source
- STAT+: Latigo reports mid-stage success for would-be rival to Vertex’s pain drug JournavxLatigo Biotherapeutics published positive data for an acute-pain drug meant to rival a Vertex medicine already on the marketSTAT · 17m ago↗ source
- Biogen shifts M&A strategy as Apellis acquisition pushes revenue above analyst expectationsBiogen officially began reporting revenue from the $5.6 billion acquisition of Apellis in the second quarter, shaking up analysts’ consensus estimates and leading to a beat.BioSpace · 6h ago↗ source
- Two biotechs sign reverse mergers to advance I&I drug, BTK inhibitorA biotech with a bispecific antibody from China and a little-known San Diego startup with a BTK inhibitor from Gossamer Bio have each signed reverse mergers to take their experimental medicines ont…